All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
RO5203648 is a potent and highly selective partial agonist of TAAR1 (Trace amine-associated receptor 1) with high affinity. RO5203648 demonstrates a novel paradigm for neuropsychiatric research.
| Molecular Weight | 231.08 |
| Formula | C9H8Cl2N2O |
| CAS Number | 1043491-54-8 |
| Form | Solid |
| Solubility (25°C) | DMSO 100 mg/mL (ultrasonic) |
| Storage | 4°C, protect from light |
| Related TAAR Products |
|---|
| Ulotaront HCl
Ulotaront HCl is a first-in-class, orally active, CNS-active TAAR1 agonist for studies related to schizophrenia. |
| Ralmitaront
Ralmitaront (RO6889450), a potent and orally active partial agonist of the trace amine-associated receptor 1 (TAAR1), acts as a neuroleptic agent. Ralmitaront can be used for the research of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder, and negative symptoms. |
| RO5263397
RO5263397 is a potent, selective, and orally available TAAR1 agonist, with EC50s of 17 and 35 nM for human TAAR1 and rat TAAR1, respectively. RO5263397 regulates wakefulness and EEG spectral composition. Antidepressant-like effect. |
| RO5166017
RO5166017 is an orally active and species-crosses TAAR1 agonist, with Ki values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively. |
| Ulotaront
Ulotaront (SEP-856) is a first-in-class, orally active, CNS-active TAAR1 agonist for use in studies related to schizophrenia. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
